Drotrecogin alfa (activated) for the treatment of meningococcal purpura fulminans [6]

Intensive Care Medicine

Volumn 29, Issue 2, 2003, Pages 337-

  Bachli, Esther B ^a   Vavricka, Stephan R ^a   Walter, Roland B ^a   Leschinger, Monika I ^b   Maggiorini, Marco ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b LILLY DEUTSCHLAND GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; C REACTIVE PROTEIN; DROTRECOGIN; HEPARIN; INTERLEUKIN 6; PROCALCITONIN; PROTEIN C;

ADULT; BLEEDING; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; ERYTHROCYTE TRANSFUSION; FEMALE; FULMINATING PURPURA; HOSPITALIZATION; HUMAN; INTENSIVE CARE; LETTER; MALE; MENINGOCOCCOSIS; OPEN STUDY; PARTIAL THROMBOPLASTIN TIME; PHASE 3 CLINICAL TRIAL; SCORING SYSTEM; SEPTIC SHOCK; SIDE EFFECT; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; TREATMENT OUTCOME;

EID: 0347926176     PISSN: 03424642     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00134-002-1605-y     Document Type: Letter

References (3)

1. Faust SN, Levin M, Harrison OB, et al (2001) Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med 345:408-416
2. Bernard GR, Vincent JL, Laterre PF, et al (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344:699-709
3. Wcisel G, Joyce D, Gudmundsdottir A, Shasby DM (2002) Human recombinant activated protein C in meningococcal sepsis. Chest 121:292-295